177Lu-edotreotide PRRT not checked

ITM Solucin GmbH · 177Lu-DOTATOC · 177Lu-Edo

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
3 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.”In the company’s words, NCT03049189 on ClinicalTrials.gov
Tested for
Neuroendocrine Tumors (2 trials), Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor and 1 more
Main trialPhase 3
“The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).”In the company’s words, NCT03049189 on ClinicalTrials.gov
Other names
177Lu-DOTATOC · 177Lu-Edo · 177Lu-DOTATOC 177Lu-Edo · Lutetium Lu 177-Edotreotide · 177Lu-edotreotide

Other drugs for Neuroendocrine Tumors

All 244 drugs for Neuroendocrine Tumors

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 27 Nov 2024 Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
Phase 3Active, not recruiting Jun 2027 Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Phase 1Recruiting Jun 2028 Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 177Lu-edotreotide PRRT

Following is part of Solo: you see every change to 177Lu-edotreotide PRRT the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in